Keros Therapeutics
KROS
155 hedge funds and large institutions have $559M invested in Keros Therapeutics in 2025 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 13 closing their positions.
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
35% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $7.49M
34% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 41
16% more capital invested
Capital invested by funds: $480M → $559M (+$78.5M)
12% more funds holding
Funds holding: 139 → 155 (+16)
1.6% less ownership
Funds ownership: 88.46% → 86.87% (-1.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$9.68M |
| 2 |
Goldman Sachs
New York
|
+$6.53M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$3.91M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.87M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$17M |
| 2 |
Morgan Stanley
New York
|
-$7.15M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$6.31M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$5.72M |
| 5 |
NM
Newtyn Management
New York
|
-$3.3M |
KROS Hedge Fund Activity: Q3 2025 in Review
155 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q3 2025, worth a combined $559M — up 16% from $480M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KROS positions and 13 closed out — a net gain of 16 holders — while 55 added to existing stakes and 41 trimmed.
The largest buyer was Western Standard LLC, adding an estimated $9.68M. The largest seller was Logos Global Management, cutting an estimated $17M.
- 155 institutional investors held Keros Therapeutics (KROS) as of Q3 2025, up from 139 in Q2 2025.
- Funds reported $559M of Keros Therapeutics stock for Q3 2025, up 16% quarter-over-quarter.
- 29 funds opened new Keros Therapeutics positions in Q3 2025 and 13 closed out, a net change of +16 holders.
- The largest Keros Therapeutics buyer in Q3 2025 was Western Standard LLC, an estimated $9.68M added.
- The largest Keros Therapeutics seller in Q3 2025 was Logos Global Management, an estimated $17M sold.
Based on aggregated 13F filings for Q3 2025.